What Biohub does

Biohub (百创汇国际生物科技（武汉）股份有限公司), originally founded as Bridgebio in 2008 and incorporated under its current legal form in Wuhan in 2011, operates a medical innovation incubation, investment, and industrialization platform that helps early- to growth-stage healthcare startups and overseas innovators enter and scale within the China market. Its core offering is a vertical incubation model integrating project sourcing and landing, angel-to-growth equity investment through strategic partner Proxima Ventures, dedicated acceleration programs (Bio-X for overseas projects and Med-X for physician-innovators), and a CDMO (Contract Development and Manufacturing Organization) platform for medical devices and IVD diagnostics, anchored by the Wuhan Optical Valley IVD Public Service Platform and the Suzhou Shishan International Medical Innovation Translation Base. The company is organized across five Chinese operating bases (Wuhan, Suzhou, Chongqing, Chengdu, Zhengzhou) plus a Boston overseas platform, with a project reserve exceeding 1,000 opportunities, more than 100 incubated and invested companies, and 30+ investment tracks spanning cardiovascular, ophthalmology, oncology, interventional therapy, IVD, immune cell therapy, and multi-target biological drugs.

The platform monetizes through professional services and project landing fees, FA (Financial Advisory) fees on transactions raising 500M+ RMB in recent three years, park operation and rental income across physical infrastructure totaling an estimated 20,000+ square meters (including 10,000-level and 100,000-level GMP cleanrooms and CDMO production lines), and investment returns from the incubation-plus-investment model. Customer segments include domestic medical innovation startups, international medtech and biotech projects seeking China entry, clinical experts and physician-inventors commercializing innovations, and Chinese local governments and biopharma parks seeking to attract high-quality medical innovation projects. The company pursues this customer base via a sales-led, ecosystem-anchored go-to-market supported by annual flagship events (华创会, 华创杯 Entrepreneurship Competition, BIO-X and MED-X Demo Day) and international delegation programs.

In 2026 Biohub significantly extended its scope beyond traditional incubation infrastructure with two strategic launches: an open-source AI model for protein design targeted at drug discovery (2026-06) and a five-year Virtual Biology Initiative anchored by a $500 million commitment ($100M for coordinated worldwide data generation, $400M for internal data generation and next-generation technologies in imaging, molecular engineering, and cryo-electron tomography), executed with the Allen Institute, Arc Institute, Broad Institute, Human Cell Atlas, Human Protein Atlas, Wellcome Sanger Institute as core partners and NVIDIA as compute partner. These moves reposition the firm from a regional China medtech incubator toward a global AI-accelerated biology platform, though the depth of in-house AI research capability is not yet disclosed.

Name

Biohub

Legal name

百创汇国际生物科技（武汉）股份有限公司

Website

https://bridgebiomed.com

Company type

Private

Founded year

2011

Operating status

Operating

Headcount range

51–100 employees

Short description

Biohub (百创汇) is a Wuhan-headquartered medical innovation incubation, investment, and industrialization platform serving early-stage startups, overseas medtech projects, and physician-innovators entering the China market across five Chinese parks plus Boston, with an integrated CDMO platform and Proxima Ventures-backed investment arm.

Ownership category

akta.pro rank

Product category

Medical Innovation Incubation and Investment

NAICS

Scientific Research and Development Services (5417), Research and Development in the Physical, Engineering, and Life Sciences (54171), Medical and Diagnostic Laboratories (6215)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

GMP Quality, Validation & Regulatory Support (GMP/CSV/Qualification) (HLAGAGAL)

Keywords

• Medical innovation incubation
• Healthcare venture capital
• Medical device CDMO
• Biomedical acceleration programs
• Clinical innovation platform

Headquarters

HQ city

Wuhan

HQ country

China

HQ region

Asia

Offices6 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Infrastructure, Operations, Technology or R&D, Marketing or Sales, Supply Chain

Revenue model

1. Project Landing and Incubation Services: Fees charged for project landing, incubation, and acceleration services including company registration, CFDA/NMPA regulatory pathway consulting, market entry, and customized acceleration services for international medtech projects entering China.
2. Investment Returns: Returns generated from direct investment in portfolio companies through the 'incubation plus investment' model, including equity gains from early-stage medical innovation companies in cardiovascular, ophthalmology, oncology, and other therapeutic areas.
3. Financial Advisory (FA) Services: Professional financial advisory services for early-stage incubation projects and healthcare companies, including need identification, strategic planning, business plan adjustment, and capital introduction. Completed more than 10 transactions raising over 500 million RMB in recent 3 years.
4. Park Operation and Rental Income: Revenue from operating medical innovation parks in Wuhan, Suzhou, Chongqing, Chengdu, and Zhengzhou, including rental income from offices, laboratories, GMP facilities, and associated services to tenant companies.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels8 records

Core offering

Biohub (百创汇) operates a medical innovation incubation, investment, and industrialization platform that runs five domestic medical innovation parks and a Boston overseas platform. It provides end-to-end services for medical innovation startups, including early-stage venture investment, dedicated acceleration programs (Bio-X for overseas projects and Med-X for clinician entrepreneurs), CDMO manufacturing capabilities with GMP-standardized cleanrooms, regulatory (NMPA/CFDA) consulting, and market entry support. The company targets cardiovascular, ophthalmology, oncology, IVD, and interventional therapy sectors.

Product overview

Biohub (百创汇) is a comprehensive medical innovation incubation, investment, and industrialization platform operating as a platform-plus-multiple-modules architecture. The core Biohub Platform serves as the umbrella service, supplemented by specialized incubation programs (Bio-X for overseas projects and Med-X for clinician entrepreneurs), CDMO manufacturing platform, technical services, market channel services, and financing advisory. The company operates physical innovation parks in Wuhan, Suzhou, Chongqing, Chengdu, and Zhengzhou, providing one-stop services from project landing, R&D, GMP production, clinical trials, registration to market commercialization. The platform focuses on cardiovascular, ophthalmology, cancer diagnosis, IVD, immune cell therapy, and multi-target biological drugs sectors.

Differentiator

Problem solved

Functional benefit

Products and services

• Biohub Platform (百创汇) Medical innovation incubation, investment, and industrialization platform providing comprehensive services from project introduction, incubation, acceleration, to commercialization in the healthcare sector, targeting medical innovation startups across cardiovascular, ophthalmology, cancer diagnostics, IVD, immune cell therapy, and multi-target biological drugs.
• Bio-X Acceleration Program (BIO-X 海外项目孵化加速计划) 180-day remote acceleration program for overseas innovative medical projects seeking to enter the China market, culminating in a Demo Day with potential investors and partners. Provides CFDA/NMPA pathway consulting, market feasibility analysis, Demo Day, and investment matchmaking.
• Med-X Acceleration Program (MED-X 医生创业孵化计划) One-stop vertical incubation program tailored for Chinese clinical experts, doctors, and physician-inventors interested in medical innovation and entrepreneurship, providing support from concept to commercialization including entrepreneurial coaching, CDMO access, investment matchmaking, clinical resource matching, and market promotion.
• CDMO Platform (原型工厂) Medical device CDMO platform providing ODM/OEM/CDMO resources for projects from proof of concept, prototyping to industrialization and commercialization, including GMP-standardized production workshops (10,000-level and 100,000-level cleanrooms) and a public experimental center with nearly 100 instruments.
• Wuhan Optical Valley IVD Public Service Platform First CDMO prototype in China for diagnostic reagents, providing 3,500 sqm of public laboratory, R&D, pilot production, clinical trials, registration and production services, including public experimental center, GMP production workshops, diagnostic reagent production line, and medical device production line.
• Suzhou Shishan International Medical Innovation Base 14,713.79 sqm medical device innovation park focusing on cardiovascular, ophthalmology, and respiratory clinical sectors, with GMP production workshops, cleanroom facilities, maker spaces, R&D offices, and a 70 million RMB angel fund. Recognized as a Jiangsu Provincial-level science and technology business incubator.
• Chongqing Xiantao Data Valley Smart Medical Incubator 1,400 sqm smart medical industry incubator focusing on high-end medical devices, AI+medical treatment, medical informatization, wearable devices, and smart medicine, including service hall, entrepreneur coffee area, multi-function roadshow hall, project exhibition area, and shared independent workstations.
• Chengdu Smart Medical Industry Incubator Provincial-level 1,073 sqm smart medical industry incubator leveraging Chengdu's regional advantages to build 3-5 local smart medical unicorn enterprises, focusing on smart medical and central-western China regional innovation resources.
• Zhengzhou Bridgebio Independent Clinical Laboratory Third-party medical testing platform including clinical microbiology testing services, entrepreneurial coaching, policy support. Partners with global leading clinical microbiology technology teams and France's largest independent microbiology testing laboratory.
• Technical Services Services including technology transfer, consulting and evaluation, project declaration, technology development, new technology launching, and academic training and exchanges.
• Market Channel Services Brand market activities including themed salons, international entrepreneurship competitions, bio-themed professional forums, and cross-border inspection services.
• Financing Advisory Services (FA Services) Professional financial advisory for healthcare sector including need identification, strategic planning, business assessment, connecting with right capital, negotiation and transaction support. Recent 3 years: 10+ transactions, 500M+ RMB raised.
• Open-Source AI Protein Design Model Open-source AI model for protein design in drug discovery. The model generates novel protein sequences and structures for therapeutic applications.
• Virtual Biology Initiative Five-year initiative to create the data foundation and technologies needed to build predictive AI models of the human cell, encompassing data generation in imaging, molecular engineering, and cryo-electron tomography. Field-sales effort targeting leading global research institutions.

Quantifiable outcome

• Shortens the industrialization process of international innovative medical projects by 1-2 years
• +4 more outcomes

Named customers15 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature5 records

Partnerships

13 partnerships are on record, tiered flagship, core and minor.

• Allen InstituteflagshipStrategic or Co-development Partner · 29 April 2026A leading global biomedical research institution partnering in the Virtual Biology Initiative, a five-year effort to create the open data foundation for AI-accelerated biology with a $500 million commitment from Biohub.
• Arc InstituteflagshipStrategic or Co-development Partner · 29 April 2026Partnering in the Virtual Biology Initiative to build predictive AI models of the human cell through coordinated worldwide data generation and technology development.
• Broad InstituteflagshipStrategic or Co-development Partner · 29 April 2026Partnering in the Virtual Biology Initiative, contributing to the global effort to create the data foundation for AI-accelerated biology.
• Human Cell AtlasflagshipStrategic or Co-development Partner · 29 April 2026Partnering in the Virtual Biology Initiative to generate and coordinate human cell data supporting the development of predictive AI models of biology.
• Human Protein AtlasflagshipStrategic or Co-development Partner · 29 April 2026Partnering in the Virtual Biology Initiative, contributing protein atlas data to support AI-accelerated biology research.
• Wellcome Sanger InstituteflagshipStrategic or Co-development Partner · 29 April 2026Partnering in the Virtual Biology Initiative to contribute genomic and biological data to the open data foundation for AI-accelerated biology.
• NVIDIAcoreTechnology or Integration · 29 April 2026Serving as a key technology partner providing accelerated computing infrastructure for the Virtual Biology Initiative's AI model training and data generation efforts.
• 武汉光谷生物城 (Wuhan Optical Valley Biolake)coreStrategic or Co-development Partner百创汇 partnered with Wuhan Optical Valley Biolake in 2011 to build China's first medical device CDMO prototype platform and the Wuhan Optical Valley IVD Platform.
• 苏州高新区 (Suzhou High-Tech Zone / 苏高新创投)coreStrategic or Co-development Partner百创汇 partnered with Suzhou High-Tech Zone to establish the Suzhou Shishan International Medical Innovation Transformation Base, a 14,713.79 sqm facility. Suzhou High-Tech Zone also provides venture capital guidance fund support for the 70 million RMB angel fund.
• 重庆渝北区 (Chongqing Yubei District)coreStrategic or Co-development PartnerChongqing Yubei District government partnered with 百创汇 in 2018 to jointly build the global smart medical industry cluster and incubation center in Xiantao Data Valley.
• 武汉协和医院 (Wuhan Union Hospital)minorStrategic or Co-development Partner百创汇 technical department cooperates with Wuhan Union Hospital for potential collaboration and technology transfer activities.
• 重庆医科大学附属医院 (Affiliated Hospitals of Chongqing Medical University)minorStrategic or Co-development Partner百创汇 technical department maintains ongoing cooperation discussions with affiliated hospitals of Chongqing Medical University for potential clinical collaboration and technology transfer.
• IBESA (International Bio-Environmental Sciences Association)minorStrategic or Co-development Partner百创汇 initiated the establishment of IBESA, the largest international pharmaceutical industry alliance in central and western China, signing contracts with 50+ international parks, associations, and enterprises to build an international exchange platform.

Scale indicators9 records

Recent moves13 records

Expansion highlights5 records

Broad incumbents

• BGI Group: BGI Group operates a major Chinese genomics business with extensive BGI bio-parks (incubator infrastructure) and incubation services for biotech startups. It is comparable to Biohub in running Chinese bio-incubator parks with services and investment activities, though anchored in genomics.
• Pharmaron: Pharmaron is a major Chinese CRO/CDMO offering drug discovery, preclinical, CMC and manufacturing services globally. It is comparable to Biohub as a CDMO platform serving innovative medical projects but with a much broader small-molecule and biologics service portfolio.
• Wuxi AppTec: Wuxi AppTec is the largest Chinese CRO/CDMO with global operations spanning small molecule, biologics, and cell/gene therapy services, plus investment and incubation activities. It is a broad incumbent that overlaps with Biohub in CDMO and incubation services but at vastly greater scale and geographic reach.
• Asymchem Laboratories: Asymchem is a leading Chinese CDMO specializing in small molecule API and CMC services with global clients. It is comparable to Biohub as a CDMO serving innovative drug and device developers, but operates purely in manufacturing without the incubator/investor overlay.

Direct peers

• Suzhou BioBAY (Suzhou Biomedical Industry Park): Suzhou BioBAY is one of China's leading biomedical industry parks, providing incubation, GMP facilities and shared infrastructure for hundreds of biotech and medtech startups. It directly competes with Biohub's Suzhou Shishan park in attracting tenants and innovation projects in the same geographic market.
• Viva Biotech: Viva Biotech is a Chinese biotech incubator and investment platform providing shared laboratory infrastructure, incubation services and equity investment to early-stage biotech startups. It is directly comparable to Biohub in its combination of incubation, CDMO-adjacent services, and venture investment in healthcare.
• JOINN Biologics: JOINN Biologics is a Chinese preclinical CRO/CDMO with GLP toxicology, bioanalysis and biologics manufacturing services. Like Biohub, it serves as an integrated services partner for innovative healthcare companies moving from R&D through regulatory and manufacturing stages in China.
• Tigermed (Hangzhou Tigermed): Tigermed is a leading Chinese clinical CRO that has expanded into preclinical services, CDMO capabilities, and healthcare investment. Like Biohub, it serves as a one-stop services platform for innovative biotech and medtech companies seeking China market entry, regulatory approval, and commercialization.

Emerging players

• HitGen: HitGen is a Chengdu-based Chinese drug discovery CRO built around DNA-encoded library (DEL) technology, serving global biotech clients. It is comparable to Biohub as a regionally based Chinese biotech services provider supporting innovation, though focused on early-stage small molecule discovery rather than CDMO/incubation.
• Tus-Holdings (TusPark): Tus-Holdings operates one of China's largest science park and incubator networks, including dedicated biomedical parks, providing incubation, investment and real estate services to startups. It is comparable to Biohub as a Chinese innovation park operator with healthcare exposure, though at a much larger national scale.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/Bridgebiomed
• LinkedInlinkedin.com/company/wuhan-optics-valley-bridgebio-international-corporation

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Biohub